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Abstract
Background: Septic thrombophlebitis is an iatrogenic life-threatening disease associated with use
of central venous devices and intravenous (IV) therapy. In cancer patients receiving chemotherapy,
vein resection or surgical thrombectomy in large central venous lines is time-consuming, can delay
administration of chemotherapy, and therefore can compromise tumor control. Experience with
thrombolysis has been published for catheter-related thrombosis but for septic thrombosis, this
experience is scarce.
Results: We describe three patients with cancer and septic thrombophlebitis of central veins
caused by Staphylococcus aureus treated with catheter removal, thrombolysis, and intravenous (IV)
antibiotics. In our reported cases, an initial bolus of 250,000 international units (IU) of streptokinase
administered during the first h followed by an infusion of 20,000–40,000 IU/h for 24–36 h through
a proximal peripheral vein was sufficient to dissolve the thrombus. After thrombolyisis and
parenteral antibiotic for 4–6 weeks the septic thrombosis due to Staphylococcus aureus solved in all
cases. No surgical procedure was needed, and potential placement of a catheter in the same vein
was permitted.
Conclusion:  Thrombolysis with streptokinase solved symptoms, cured infection, prevented
embolus, and in all cases achieved complete thrombus lysis, avoiding permanent central-vein
occlusion.
Background
Septic thrombophlebitis is an iatrogenic life-threatening
disease associated with use of central venous devices and
intravenous (IV) therapy. [1-3] Sole use of antimicrobials
is rarely effective for controlling infection, requiring
removal of the device and anticoagulation but in some
cases a more aggressive approach such as resection of the
affected vein [2,4-7] or trombectomy is needed [8]. Vein
resection or surgical thrombectomy is time-consuming in
large central venous lines, has a high rate of
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complications, can delay administration of chemother-
apy, and therefore delay or impede tumor control. Experi-
ence with thrombolysis has been published for catheter-
related thrombosis [9-13] but for septic thrombosis, this
experience is scarce. [14,15] Herein, we describe three
women with cancer and septic thrombophlebitis due to
Staphylococcus aureus methicillin sensitive, who failed to
resolve with catheter removal, parenteral antibiotics, and
anticoagulation therapy and who were successfully
treated with low-dose streptokinase fibrinolysis. All
patients were receiving chemotherapy through non-tun-
neled polyurethane, single-lumen catheters placed in the




This was the case of a woman 59-years-of-age with papil-
lary ovarian adenocarcinoma. She had been treated dur-
ing the previous 10 years with 10 mg/day of prednisone
for rheumatoid arthritis. A first central-vein catheter was
placed for adjuvant chemotherapy and removed 4 months
later with no complications. A new catheter was set in
place 8 months later after documenting tumor relapse;
however, one day later the patient developed pain at the
insertion site and fever (39°C), and chills. An abscess at
insertion site was found and the catheter was removed.
Blood cultures, purulent secretion, and catheter tip were
positive for Staphylococcus aureus. Intravenous dicloxacil-
lin was initiated and amikacin was added 1 day later, but
fever and positive blood cultures persisted. Echo-Doppler
documented thrombosis of brachiocephalic trunk and
computed tomography (CT) scan showed a thrombus
reaching brachiocephalic trunk and superior vena cava
(Figure 1a); subcutaneous (SC) enoxaparin was initiated.
Vancomycin was started because fever and bacteremia
persisted, with no clinical improvement. Seven days after
beginning with antibiotics, the patient received an initial
bolus of 250,000 international units (IU) of streptokinase
administered in 1 h followed by an infusion of 40,000 IU
per h for 24 h through a peripheral vein. One day after
thrombolysis began, fever and positive blood cultures dis-
appeared. Full permeability of right brachiocephalic vein
and superior vena cava was documented by CT scan (Fig-
ure 1b). The patient completed 4 weeks of parenteral anti-
biotics, but died 1 month later with peritoneal
carcinomatosis-related intestinal occlusion. Necropsy
study showed neither thrombosis nor obstruction of great
central veins.
Case 2
A 42-year-old woman with breast cancer stage IIIB was
started on chemotherapy. Four months later, she was
admitted with fever, shivering, and painful erythematous
lesions disseminated in legs and arms. The patient was ini-
tiated on IV vancomycin and amikacin, and after initial
blood cultures grew oxacillin-sensitive S. aureus. The cath-
eter was removed and antibiotics were changed to
dicloxacillin and amikacin. Initial echo-Doppler for all
limbs did not demonstrate obstruction to blood flow.
Chest roentgenogram showed bilateral, multiple,
rounded, irregular, non-cavitated opacities. Transthoracic
echocardiography did not show heart valve vegetations,
but did show a mobile hyper-reflectant image in superior
vena cava extending to right atrium, suggestive of throm-
bus. Fever persisted and new painful nodular erythemath-
ous lesions appeared in both limbs that evolved into
abscesses, but neither purulent skin lesions nor blood cul-
tures grew microorganisms. A second transthoracic
echocardiogram performed 9 days later showed persist-
ence of the same pediculated lesion that measured 40 × 10
× 10 mm. The patient was thrombolyzed with the same
doses of streptotokinase; 24 h later, she had no fever, all
symptoms resolved and transthoracic echocardiography
performed 9 days later showed no lesions. She completed
6 weeks with IV antimicrobials. A month later, the sched-
uled mastectomy was performed the patient received 11
courses of weekly paclitaxel. Ten months later, the patient
is asymptomatic with no evidence of tumor activity.
Case 3
A 57-year-old woman with ovarian adenocarcinoma stage
IV metastatic to lungs with a catheter placed in the right
subclavian vein, through which she received four cycles of
CT scan showing thrombus before and after thrombolysis Figure 1
CT scan showing thrombus before and after throm-
bolysis. 1a. CT scan of superior vena cava with intravenous 
contrast infusion showing a thrombus before streptokinase 
infusion. 1b. CT scan of superior vena cava with intravenous 
contrast infusion three days after thrombolysis showing no 
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carboplatin and paclitaxel. One week after the last chem-
otherapy cycle, she developed fever and pain in the right
shoulder and two days later presented to the emergency
room. At admission, the patient had persistent shoulder
pain, anorexia, and an enlarging, painful mass in right
shoulder, with an indurated, extremely tender area in
right sternoclavicular joint and edema in right arm. She
was febrile, hypotensive, and tachycardic. Oxacillin-sensi-
tive Staphylococcus aureus grew in blood and catheter tip,
and was started on dicloxacillin and amikacin. Echo-Dop-
pler revealed a 4-cm long thrombus within the right sub-
clavian vein partially occluding the right jugular vein. No
intracardiac thrombus or valvular lesions were observed
in the Echocardiogram. CT scan showed a large collection
of liquid in right shoulder sternoclavicular joint. The
patient received an initial streptokinase bolus of 250,000
IU and one 12-h infusion of 20,000 U/h, followed by
enoxaparin 60 mg BID. Twenty four hours later, Echo-
Doppler showed patent right subclavian and jugular
veins. She completed 3 weeks of enoxaparin and then
changed to oral anticoagulation. Technetium bone scan
showed evidence of ipsilateral clavicle osteomyelitis. She
received IV antibiotics for 4 weeks followed by oral
dicloxacillin plus rifampin for 28 weeks. After treatment
the bone scan did not have evidence of osteomyelitis and
8 months later the patient had normal shoulder function
without arm edema.
Discussion
Intravascular infection and thrombosis are two of the
most serious complications related to central venous cath-
eter use. Central vein thrombosis was described as a com-
plication of catheters in 1971 [2]. Symptoms were present
in <4% of patients with central venous catheter when
venography showed thrombosis [2]. Neoplastic disease
often creates a thrombogenic state, through inflammation
mediators, tumor necrosis factor, platelet activation, as
well as a procoagulant substances released by tumor cells
[15]. In addition, long indwelling lines increase risk for
thrombosis, reported in 0.06-32% of patients, although
the risk changes with type of catheter, neoplasia, chemo-
therapy regimes and radiation [16]. The complications of
catheter-related thrombosis are similar although not as
frequently as has been described for lower limb thrombo-
sis [16]. It can produce pulmonary embolism. The trom-
bus can become infected with persistent bacteremia and
septic embolization ensue [17]. It has been recognized
that CVC infection increases the risk of thrombosis [18]
even though we believe that the incidence of septic throm-
bosis with persistent refractory bacteremia as the cases
herein described is uncommon, in a recent review CVC
associated thrombosis this complication is not men-
tioned [17]. For the last 6 years at a hospital where we
placed >1,100 long indwelling catheters for cancer
patients annually we have observed approximately one
case every two years.
Standard therapy for catheter associated septic thrombosis
includes antibiotics, catheter removal, full heparin
anticoagulation, and venotomy. The latter is technically
impossible for great central veins, although surgical
thrombectomy has been successfully performed [8] and
medical lysis of the thrombus is feasible [13,14]. We
describe successful lysis of septic thrombosis with low-
dose streptokinase infusion through a peripheral vein
proximal to central great vein affected and no surgical or
invasive procedure performed. This approach was first
reported with a high percentage of success in catheter-
Table 1: Demographic and clinical characteristics of the patients described
C a s e 123
G e n d e r FFF
Age 59 42 57
Cancer site Ovarian (relapse) Breast stage III-B Ovarian stage IV
Time of catheter stay (days) before 
symptoms
11 5 5 6 3
Thrombus site Superior vena cava Superior vena cava extended to 
right atrium
Subclavian and yugular veins
Days of antimicrobials before 
thrombolysis
71 9 6
Indication for thrombolyis Persitent fever and bacteremia. Persistent fever and septic 
embolization
Persitent fever and septic 
embolization
Staphylococcus aureus methicillin 
sensible
+++
Streptokinase dose 250,000 IU hr. bolus + 40,000 us/
hr for 24 hrs.
250,000 IU us/hr bolus. 250,000 us 1 hr. bolus + 25,000 us/
hr for 12 hrs.
Thrombus lysis 100% 100% 100%
A R D S * N oN oN o
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related thrombosis in the early 1980s, allowing to main-
tain vein patency [4,6] using streptokinase, urokinase, and
more recently, recombinant-tissue plasminogen activator,
[13,14]. In our reported cases, streptokinase administered
as initial bolus of 250,000 IU during 1 hour followed by
infusion of 20,000-40,000 IU/h for 24-36 hours through
a proximal peripheral vein was sufficient to dissolve the
thrombus Table 1. This treatment solved symptoms, cured
infection, prevented embolus, and in all cases achieved
complete thrombus lysis, avoiding permanent central-
vein occlusion. The episode of septic thrombosis due to
Staphylococcus aureus solved with continued parenteral
antibiotic for 4 to 6 weeks in all cases and no surgical pro-
cedure was required.
Conclusion
Fibrinolytic therapy with streptokinase is a therapeutic
option in the management of catheter-related septic
thrombophlebitis of the great central veins. This therapeu-
tic approach, mantain central vein patency, allowing
potential to place a new long indwelling catheter, the cor-
nerstone for cancer patients who need chemotherapy.
List of abbreviations
IV – intravenous
IU – International units
CT – Computed tomography
SC – subcutaneous
ARDS – Acute respiratory distress syndrome
Competing interests
The authors declare that we have not competing interests
in the interpretation of data or presentation of informa-
tion influenced by our personal or financial relationship
with other people or organizations.
Authors' contributions
PV – Participated in the design of the study, collected data,
wrote the manuscript, general supervision of the research
group
PCJ – Collected data, wrote the manuscript
AAB – Collected data and looked for the researches made
before related with the manuscript
JGM – Collected data and looked for the researches made
before related with the manuscript
EBL – Revised the manuscript and analysis of data
RPP – Revised the manuscript, analysis of data and final
approval of the version
All authors read and approved the final manuscript.
References
1. Bayer AS, Scheld WM: Endocarditis and intravascular infec-
tions. In: Principles and practice of infectious diseases.  Vol-
ume 1. 5th edition. Edited by: Mandell GL, Bennett JE, Dolin R. New
York: Churchill Livingstone; 2000:857-902. 
2. Andes DR, Urban AW, Acher ChW, Maki DG: Septic thrombosis
of basilic, axillary, and subclavian veins caused by a peripher-
ally inserted central venous catheter.  Am J Med 1998,
105:446-450.
3. Raad I, Luna M, Khalil S, Costerton J, Lam C, Bodey G: The relation-
ship between the thrombotic and infectious complications of
central venous catheters.  JAMA 1994, 271:1014-16.
4. Verghese A, Widrich W, Arbeit R: Central venous septic throm-
bophlebitis – The role of medical therapy.  Medicine 1985,
64:394-400.
5. Slagle DC, Gates RH: Unusual case of central vein thrombosis
and sepsis.  Am J Med 1986, 81:351-4.
6. Kaufman J, Demas C, Stark K, Flancbaum L: Catheter-related sep-
tic central venous thrombosis – Current therapeutic
options.  West J Med 1986, 145:200-3.
7. Hoffman MJ, Greenfield LJ: Central venous septic thrombosis
managed by superior vena cava Greenfield filter and venous
thrombectomy: a case report.  J Vasc Surg 1986, 4:606-11.
8. Kniemeyer HW, Grabitz K, Buhl R, Wust HJ, Sandmann W: Surgical
treatment of septic deep venous thrombosis.  Surgery 1995,
118:49-53.
9. Seigel EL, Jew AC, Delcore R, Iliopoulos J, Thomas J: Thrombolytic
therapy for catheter-related thrombosis.  Am Surg 1993,
166:716-9.
10. Fraschini G, Jadeja J, Lawson M, Holmes F, Carrasco H, Wallace S:
Local infusion of urokinase for the lysis of thrombosis associ-
ated with permanent central venous catheters in cancer
patients.  J Clin Oncol 1987, 5:672-8.
11. Rubenstein M, Creger WP: Successful streptokinase therapy for
catheter-induced subclavian vein thrombosis.  Arch Intern Med
1980, 140:1370-1.
12. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER: Recom-
binant tissue plasminogen activator (alteplase) for restora-
tion of flow in occluded central venous access devices: a
double-blind placebo-controlled trial – The Cardiovascular
Thrombolytic to Open Occluded Lines (COOL) Efficacy
Trial.  J Vasc Interv Radiol 2001, 12:951-5.
13. Haire WD: Techniques in dosing for thrombolysis of occluded
central venous catheters.  Tech Vasc Interv Radiol 2001, 4:127-30.
14. Schranz D, Haugwitz D, Zimmer B, Schumacher R: Successful lysis
of a septic thrombosis of the superior vena cava using
recombinant tissue-plasminogen activator.  Klin Padiatr 1991,
203:363-5.
15. Lewis JA, LaFrance R, Bower RH: Treatment of an infected sili-
cone right atrial catheter with combined fibrinolytic and
antibiotic therapy: case report and review of the literature.
J Parenter Enteral Nutr 1989, 13:92-8.
16. Van Rooden CJ, Tesselaar ME, Osanto S, Rosendaal FR, Huisman MV:
Deep vein thrombosis associated with central venous cathe-
ters – a review.  J Thromb Haemost 2005 in press.
17. Devie-Hubert I, Carlier M, Pozzo Di Borgo C: Venous thrombosis
on central catheters in oncology.  Rev Med Intern 1996, 17:821-5.
18. Van Rooden CJ, Schippers EF, Barge RM, Rosendaal FR, Guiot HF, van
der Meer FJ, Meinders AE, Huisman MV: Infectious complications
of central venous catheters increase the risk of catheter-
related thrombosis in hematology patients: a prospective
study.  J Clin Oncol 2005, 23:2655-60.